Sonnet BioTherapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • CEO Corner
  • Technology
    • Overview
    • Platform
    • Publications
  • Pipeline
    • Overview
    • SON-1010
    • SON-1210
    • SON-080
    • Clinical Trials
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Feb 18, 2025 9:15am EST

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025 8:30am EST

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025 8:00am EST

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025 9:05am EST

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025 8:35am EST

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025 9:05am EST

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024 9:20am EST

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024 8:50am EST

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 09, 2024 3:42pm EST

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 09, 2024 8:45am EST

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...12
    Next
    © 2025 Sonnet BioTherapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap